Rentschler Fill Solutions and Ultragenyx announce fill and finish agreement for the US commercial supply of Mepsevii.
Rentschler Fill Solutions GmbH announced on May 30, 2018 a collaboration with Ultragenyx Pharmaceutical, Inc. for the fill/finish production of the injectable Mepsevii (vestronidase alfa), a recombinant form of the human enzyme beta-glucuronidase, to treat patients with mucopolysaccharidosis (MPS) VII, a rare genetic disorder.
Mepsevii, developed by Ultragenyx in collaboration with Rentschler Biopharma SE in Laupheim, Germany, was approved by the US FDA in November 2017. An application for marketing approval in Europe is under review.
The drug product will be transferred from Rentschler Biopharma SE to Austria-based Rentschler Fill Solutions for fill/finish activities. Rentschler Biopharma will continue to manufacture the drug substance.
Rentschler Fill Solutions offers services for the aseptic filling and freeze drying of drug products.
Source: Rentschler Fill Solutions
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.